Hepatology research : the official journal of the Japan Society of Hepatology
The presence of portosystemic collateral vessels at start of NAs treatment increases the risk of GEVs worsening and development portosystemic encephalopathy in patients with HBV-related cirrhosis despite of improvement of liver function and successful in reducing viral loads with NAs treatment.
Clinical and experimental medicine
This study compared virologic response to entecavir monotherapy and de novo lamivudine plus adefovir (LAM + ADV) combination therapy in patients with chronic hepatitis B (CHB) with high viral load (HVL). Hepatitis B e antigen (HBeAg)-positive patients [hepatitis B virus (HBV) DNA levels >1 × 10(7) copies/ml] were assigned to LAM + ADV or entecavir ...
Advances in therapy
Novartis Pharma AG.
Objective to investigate the association between HBV genotypes and characteristics of rtA181 mutation. Methods Total of 85 chronic hepatitis B (CHB) patients who appeared rtA181 mutation after nucleos(t)ide analogs (NAs) therapy were enrolled in this study. Levels of serum ALT, AST, HBV DNA and HBsAg titers were monitored during therapy. HBV revers...
Journal of clinical and translational hepatology
Infection with hepatitis B virus (HBV) is a worldwide health problem. Chronic hepatitis B can lead to fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC). Management of the latter two conditions often requires liver transplantation. Treatment with conventional interferon or pegylated interferon alpha can clear the virus, but the rates are...
World journal of gastroenterology
Quantification of hepatitis B surface antigen (HBsAg) has been suggested to be helpful in the management of chronic hepatitis B (CHB) patients. Nucleos(t)ide analogs (NAs) are the therapy of choice for CHB and are used in the majority of CHB patients. NAs are able to induce hepatitis B virus (HBV) viral suppression, normalization of alanine aminotr...
Chronic hepatitis B virus (HBV) infection is endemic in the Asian-Pacific region, and reactivation of HBV post-cancer chemotherapy has become an emerging clinical challenge. Patients with detectable serum HBV DNA before chemotherapy and those receiving intensive chemotherapy are particularly at a risk of HBV reactivation. Most patients with HBV rea...
Encyclopedia of Virology, Five-Volume Set
Hepatitis B virus is a member of the family Hepadnaviridae and is responsible for causing acute and chronic liver infections in humans. Current estimates of the total number of chronic carriers of the virus are put at 350 million worldwide. These individuals run the risk of developing cirrhosis of the liver and hepatocellular carcinoma in later lif...